Dongfeng Feng Yaping Guan Mingguo Liu Shuqian He Weipeng Zhao Beibei Yin Jing Liang Yan Li Jun Wang
10.3389/fimmu.2021.608292
Front Immunol
2021 May 31;12:608292.
atezolizumab hyperprogressive disease immune checkpoint inhibitor pembrolizumab triple-negative breast cancer
CC BY
https://pubmed.ncbi.nlm.nih.gov/34135884/
Antibodies, Monoclonal, Humanized / therapeutic use Antineoplastic Agents, Immunological / therapeutic use Carcinoma, Ductal / drug therapy Immune Checkpoint Inhibitors / therapeutic use Immunotherapy / methods Triple Negative Breast Neoplasms / drug therapy
Antibodies, Monoclonal, Humanized / therapeutic use Antineoplastic Agents, Immunological / therapeutic use Carcinoma, Ductal / drug therapy Immune Checkpoint Inhibitors / therapeutic use Immunotherapy / methods Triple Negative Breast Neoplasms / drug therapy Case Reports Research Support, Non-U.S. Gov't Review Aged Disease Progression Female Humans Neoplasm Metastasis Neoplasm Staging Remission Induction Treatment Outcome Antibodies, Monoclonal, Humanized Antineoplastic Agents, Immunological Immune Checkpoint Inhibitors atezolizumab pembrolizumab
PMC8201609
34135884
Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature
2021